Suppr超能文献

16 种阿什肯纳兹犹太人遗传病的携带者筛查和产前诊断经验。

Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases.

机构信息

Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, NY 10029, USA.

出版信息

Hum Mutat. 2010 Nov;31(11):1240-50. doi: 10.1002/humu.21327.

Abstract

The success of prenatal carrier screening as a disease prevention strategy in the Ashkenazi Jewish (AJ) population has driven the expansion of screening panels as disease-causing founder mutations have been identified. However, the carrier frequencies of many of these mutations have not been reported in large AJ cohorts. We determined the carrier frequencies of over 100 mutations for 16 recessive disorders in the New York metropolitan area AJ population. Among the 100% AJ-descended individuals, screening for 16 disorders resulted in ∼1 in 3.3 being a carrier for one disease and ∼1 in 24 for two diseases. The carrier frequencies ranged from 0.066 (1 in 15.2; Gaucher disease) to 0.006 (1 in 168; nemaline myopathy), which averaged ∼15% higher than those for all screenees. Importantly, over 95% of screenees chose to be screened for all possible AJ diseases, including disorders with lower carrier frequencies and/or detectability. Carrier screening also identified rare individuals homozygous for disease-causing mutations who had previously unrecognized clinical manifestations. Additionally, prenatal testing results and experience for all 16 disorders (n = 574) are reported. Together, these data indicate the general acceptance, carrier frequencies, and prenatal testing results for an expanded panel of 16 diseases in the AJ population.

摘要

作为一种疾病预防策略,产前携带者筛查在阿什肯纳兹犹太(AJ)人群中取得了成功,随着致病的创始人突变的确定,筛查面板不断扩大。然而,许多这些突变的携带者频率在大型 AJ 队列中尚未报道。我们确定了纽约都会区 AJ 人群中 16 种隐性疾病的 100 多个突变的携带者频率。在 100% AJ 血统的个体中,对 16 种疾病进行筛查,导致约 1/3.3 是一种疾病的携带者,约 1/24 是两种疾病的携带者。携带者频率范围从 0.066(1/15.2;戈谢病)到 0.006(1/168;肌营养不良),平均比所有筛查者高约 15%。重要的是,超过 95%的筛查者选择对所有可能的 AJ 疾病进行筛查,包括携带者频率和/或可检测性较低的疾病。携带者筛查还确定了罕见的纯合子疾病致病突变个体,这些个体以前没有被识别出临床表现。此外,还报告了所有 16 种疾病(n=574)的产前检测结果和经验。这些数据共同表明,在 AJ 人群中,对 16 种疾病的扩展面板进行了普遍接受、携带者频率和产前检测结果。

相似文献

2
Comprehensive population screening in the Ashkenazi Jewish population for recurrent disease-causing variants.
Clin Genet. 2017 Apr;91(4):599-604. doi: 10.1111/cge.12834. Epub 2016 Aug 22.
3
Premarital and prenatal screening for cystic fibrosis: experience in the Ashkenazi Jewish population.
Genet Med. 2004 Sep-Oct;6(5):415-20. doi: 10.1097/01.gim.0000139510.00644.f7.
4
Carrier screening for mucolipidosis type IV in the American Ashkenazi Jewish population.
Am J Hum Genet. 2002 Apr;70(4):1023-7. doi: 10.1086/339519. Epub 2002 Feb 13.
7
The Ashkenazi Jewish carrier screening panel: evolution, status quo, and disparities.
Prenat Diagn. 2014 Dec;34(12):1161-7. doi: 10.1002/pd.4446. Epub 2014 Jul 31.
8
Carrier testing for Ashkenazi Jewish disorders in the prenatal setting: navigating the genetic maze.
Am J Obstet Gynecol. 2014 Sep;211(3):197-204. doi: 10.1016/j.ajog.2014.02.001. Epub 2014 Feb 5.
9
Prenatal genetic screening in the Ashkenazi Jewish population.
Clin Perinatol. 2001 Jun;28(2):367-82. doi: 10.1016/s0095-5108(05)70089-0.

引用本文的文献

1
Genetic disease risks of under-represented founder populations in New York City.
PLoS Genet. 2025 Jun 24;21(6):e1011755. doi: 10.1371/journal.pgen.1011755. eCollection 2025 Jun.
2
Applications of genome sequencing as a single platform for clinical constitutional genetic testing.
Genet Med Open. 2024 Mar 20;2:101840. doi: 10.1016/j.gimo.2024.101840. eCollection 2024.
3
Genetic disease risks of under-represented founder populations in New York City.
medRxiv. 2024 Sep 28:2024.09.27.24314513. doi: 10.1101/2024.09.27.24314513.
5
Biochemical characterization of patients with dihydrolipoamide dehydrogenase deficiency.
JIMD Rep. 2023 Aug 4;64(5):367-374. doi: 10.1002/jmd2.12382. eCollection 2023 Sep.
6
Glycogen storage diseases: An update.
World J Gastroenterol. 2023 Jul 7;29(25):3932-3963. doi: 10.3748/wjg.v29.i25.3932.
7
Long-read HiFi sequencing of NUDT15: Phased full-gene haplotyping and pharmacogenomic allele discovery.
Hum Mutat. 2022 Nov;43(11):1557-1566. doi: 10.1002/humu.24457. Epub 2022 Sep 12.
9
Evaluating the model of offering expanded genetic carrier screening to high school students within the Sydney Jewish community.
J Community Genet. 2022 Feb;13(1):121-131. doi: 10.1007/s12687-021-00567-8. Epub 2021 Nov 30.
10
A collaborative genetic carrier screening model for the British Ashkenazi Jewish community.
J Community Genet. 2022 Feb;13(1):133-135. doi: 10.1007/s12687-021-00568-7. Epub 2021 Nov 29.

本文引用的文献

1
Type 1 Gaucher disease: significant disease manifestations in "asymptomatic" homozygotes.
Arch Intern Med. 2010 Sep 13;170(16):1463-9. doi: 10.1001/archinternmed.2010.302.
3
When diseases disappear--the case of familial dysautonomia.
N Engl J Med. 2009 Oct 22;361(17):1622-5. doi: 10.1056/NEJMp0809587.
4
Development of genomic DNA reference materials for genetic testing of disorders common in people of ashkenazi jewish descent.
J Mol Diagn. 2009 Nov;11(6):530-6. doi: 10.2353/jmoldx.2009.090050. Epub 2009 Oct 8.
5
Next-generation sequencing: from basic research to diagnostics.
Clin Chem. 2009 Apr;55(4):641-58. doi: 10.1373/clinchem.2008.112789. Epub 2009 Feb 26.
6
Population screening in a Druze community: the challenge and the reward.
Genet Med. 2008 Dec;10(12):903-9. doi: 10.1097/GIM.0b013e31818d0e0f.
8
Keeping up with the next generation: massively parallel sequencing in clinical diagnostics.
J Mol Diagn. 2008 Nov;10(6):484-92. doi: 10.2353/jmoldx.2008.080027. Epub 2008 Oct 2.
9
Mutations causing severe combined immunodeficiency: detection with a custom resequencing microarray.
Genet Med. 2008 Aug;10(8):575-85. doi: 10.1097/gim.0b013e31818063bc.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验